Bevacizumab for recurrent or refractory malignant glioma
Not Applicable
- Conditions
- Recurrent or recurrent malignant glioma
- Registration Number
- JPRN-UMIN000017100
- Lead Sponsor
- The University of Tokyo Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1)ICH, =< 6 month after stroke 2)severe wound, ulcer, fracture 3)bleeding 4) >= 6 month after myocardiac infarction or pulmonary embolism 5)heart failure >= NYHA grade 2 6)uncontrollable hypertention 7)uncontrollable gastric ulcer 8)=< 1 year after gastrointestinal perforation 9)pregnant or conducting breastfeeding 10)already treated by Bevacizumab in the past
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method overall survival
- Secondary Outcome Measures
Name Time Method response rate, 6 month progression free survival, 6 month overall survival, safetiness